BRG1/BRM Inhibitor Compounds for BAF-Related Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments are inadequate for disorders associated with alterations in the BRG1 and BRM proteins, which are critical for cancer cell proliferation and tumor growth, and there is a need for effective methods to inhibit these proteins to treat related disorders such as cancer and viral infections.
Innovation Solution
Development of compounds that modulate the BAF complex by inhibiting BRG1 and/or BRM, including specific structures of N-(1-(4(4-(6-(2,6-dimethylmorpholino)pyridin-2-yl)thiazol-2-yl)amino)-3-methoxy-1-oxopropan-2-yl)-1-(methylsulfonyl)-1H-pyrrole-3-carboxamide and related derivatives, which can be administered to reduce the activity of these proteins and induce apoptosis in cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for disorders associated with BRG1 and BRM alterations, then existing therapeutic options are available, but treatment effectiveness is inadequate
Solution Approach 1:
The patent employs parameter changes by developing compounds with specific molecular structures ( featuring hydroxamate, hydrazone, or oxime functional groups) that can effectively bind to and inhibit BRG1 and BRM proteins. This chemical parameter modification enables the compounds to selectively target the ATPase activity of these proteins, thereby improving treatment effectiveness for disorders associated with BRG1 and BRM alterations while providing a new therapeutic approach beyond existing options
2Productivity
If BRG1 and BRM activity is inhibited to treat cancer, then tumor growth is reduced, but drug-resistant forms may develop
Solution Approach 1:
The patent applies local quality by designing compounds with specific functional groups (hydroxamate, hydrazone, oxime) that target particular regions of the BRG1 and BRM proteins, specifically the ATPase domain. This localized targeting approach enhances the compounds' ability to inhibit tumor growth while reducing the likelihood of resistance development by precisely interfering with the essential catalytic activity of these proteins
3Measurement precision
If compounds are developed to specifically inhibit BRG1 and BRM, then treatment precision is improved, but compound complexity increases
Solution Approach 1:
The patent uses intermediary compounds containing functional groups such as hydroxamate, hydrazone, or oxime that act as mediators between the administered substance and the BRG1/BRM target proteins. These intermediary functional groups enable specific binding to the ATPase domain of the proteins, achieving precise target inhibition while maintaining relatively simple overall compound structures that are feasible for drug development
Data Source
AI summary
The present disclosure features compounds useful for the treatment of BAF complex-related disorders.